Search Results - "van Vollenhoven, Ronald F"

Treat-to-target in systemic lupus erythematosus: advancing towards its implementation by Parra Sánchez, Agner R., Voskuyl, Alexandre E., van Vollenhoven, Ronald F.

“…The treat-to-target (T2T) concept has improved outcomes for patients with diabetes, hypertension and rheumatoid arthritis. This therapeutic strategy involves…”
Get full text

Tofacitinib versus Methotrexate in Rheumatoid Arthritis by Lee, Eun Bong, Fleischmann, Roy, Hall, Stephen, Wilkinson, Bethanie, Bradley, John D, Gruben, David, Koncz, Tamas, Krishnaswami, Sriram, Wallenstein, Gene V, Zang, Chuanbo, Zwillich, Samuel H, van Vollenhoven, Ronald F

“…In patients with rheumatoid arthritis, tofacitinib was associated with greater reductions in signs and symptoms than methotrexate. Herpes zoster infections and…”
Get full text

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis by van Vollenhoven, Ronald F, Fleischmann, Roy, Cohen, Stanley, Lee, Eun Bong, García Meijide, Juan A, Wagner, Sylke, Forejtova, Sarka, Zwillich, Samuel H, Gruben, David, Koncz, Tamas, Wallenstein, Gene V, Krishnaswami, Sriram, Bradley, John D, Wilkinson, Bethanie

“…In this trial of patients with rheumatoid arthritis who were on stable doses of methotrexate, tofacitinib, a novel oral Janus kinase inhibitor, was more…”
Get full text

Sex differences in rheumatoid arthritis: more than meets the eye by van Vollenhoven, Ronald F

“…Sex differences in the prevalence of autoimmune diseases such as rheumatoid arthritis (RA) are well described, but the literature is not as clear about sex…”
Get full text

Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years by van Vollenhoven, Ronald F, Fleischmann, Roy M, Furst, Daniel E, Lacey, Stuart, Lehane, Patricia B

“…Final evaluation of the longterm safety of rituximab (RTX) in rheumatoid arthritis (RA) up to 11 years. Pooled observed case analysis of data from patients…”
Get full text

Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial by Smolen, Josef S, Prof, Emery, Paul, Prof, Fleischmann, Roy, Prof, van Vollenhoven, Ronald F, Prof, Pavelka, Karel, Prof, Durez, Patrick, Prof, Guérette, Benoît, PhD, Kupper, Hartmut, MD, Redden, Laura, MD, Arora, Vipin, PhD, Kavanaugh, Arthur, Prof

“…Summary Background Biological agents offer good control of rheumatoid arthritis, but the long-term benefits of achieving low disease activity with a biological…”
Get full text

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response by van Vollenhoven, Ronald F, Petri, Michelle A, Cervera, Ricard, Roth, David A, Ji, Beulah N, Kleoudis, Christi S, Zhong, Z John, Freimuth, William

“…To identify factors that predict response to belimumab treatment in the phase 3 BLISS trials of autoantibody-positive systemic lupus erythematosus (SLE) and…”
Get more information

Treatment of rheumatoid arthritis: state of the art 2009 by van Vollenhoven, Ronald F

“…The therapeutic options for patients with rheumatoid arthritis (RA) have changed dramatically over the past two decades, as discussed in this Review. The…”
Get full text

Integrated safety in tocilizumab clinical trials by Schiff, Michael H, Kremer, Joel M, Jahreis, Angelika, Vernon, Emma, Isaacs, John D, van Vollenhoven, Ronald F

“…The efficacy and safety of tocilizumab in patients with rheumatoid arthritis have been evaluated in a comprehensive phase 3 program. Patients from these…”
Get full text

Sustained biologic-free and drug-free remission in rheumatoid arthritis, where are we now? by Nagy, György, van Vollenhoven, Ronald F

“…The advent of new medications and new treatment strategies for rheumatoid arthritis has made it possible to achieve remission in more patients than before…”
Get full text

Preclinical Autoimmune Disease: a Comparison of Rheumatoid Arthritis, Systemic Lupus Erythematosus, Multiple Sclerosis and Type 1 Diabetes by Frazzei, Giulia, van Vollenhoven, Ronald F., de Jong, Brigit A., Siegelaar, Sarah E., van Schaardenburg, Dirkjan

“…The preclinical phase of autoimmune disorders is characterized by an initial asymptomatic phase of varying length followed by nonspecific signs and symptoms. A…”
Get full text

Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial by Dörner, Thomas, van Vollenhoven, Ronald F, Doria, Andrea, Jia, Bochao, Ross Terres, Jorge A, Silk, Maria E, de Bono, Stephanie, Fischer, Peter, Wallace, Daniel J

“…Patients with systemic lupus erythematosus (SLE) have substantial unmet medical need. Baricitinib is a Janus kinase (JAK)1 and 2 inhibitor that was shown to…”
Get full text

The association between lupus serology and disease outcomes: A systematic literature review to inform the treat-to-target approach in systemic lupus erythematosus by Kostopoulou, Myrto, Ugarte-Gil, Manuel F, Pons-Estel, Bernardo, van Vollenhoven, Ronald F, Bertsias, George

“…Introduction Serological markers such as anti-double stranded (ds)DNA antibodies and complement fractions C3/C4, are integral components of disease activity…”
Get full text

Baseline Predictors of Systemic Lupus Erythematosus Flares: Data From the Combined Placebo Groups in the Phase III Belimumab Trials by Petri, Michelle A., Vollenhoven, Ronald F., Buyon, Jill, Levy, Roger A., Navarra, Sandra V., Cervera, Ricard, Zhong, Z. John, Freimuth, William W.

“…Objective To identify predictors of moderate‐to‐severe systemic lupus erythematosus (SLE) flare in 562 patients treated with standard therapy alone in phase…”
Get full text

Transaminase Levels and Hepatic Events During Tocilizumab Treatment: Pooled Analysis of Long‐Term Clinical Trial Safety Data in Rheumatoid Arthritis by Genovese, Mark C., Kremer, Joel M., van Vollenhoven, Ronald F., Alten, Rieke, Scali, Juan Jose, Kelman, Ariella, Dimonaco, Sophie, Brockwell, Laura

“…Objective To investigate liver enzyme abnormalities and hepatic adverse events (AEs) during long‐term tocilizumab treatment for rheumatoid arthritis in…”
Get full text

Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay by Berkhout, Lea C, l'Ami, Merel J, Ruwaard, Jill, Hart, Margreet H, Heer, Pleuni Ooijevaar-de, Bloem, Karien, Nurmohamed, Michael T, van Vollenhoven, Ronald F, Boers, Maarten, Alvarez, Daniel F, Smith, Catherine H, Wolbink, Gerrit J, Rispens, Theo

“…Patients with rheumatoid arthritis (RA) can be successfully treated with tumor necrosis factor (TNF) inhibitors, including the monoclonal antibody adalimumab…”
Get more information

Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial by van Vollenhoven, Ronald F, Prof, Geborek, Pierre, MD, Forslind, Kristina, MD, Albertsson, Kristina, MD, Ernestam, Sofia, MD, Petersson, Ingemar F, MD, Chatzidionysiou, Katerina, MD, Bratt, Johan, MD

“…Summary Background Analysis of the Swedish Farmacotherapy (Swefot) trial at 12 months showed that the addition of an anti-tumour-necrosis-factor agent gave an…”
Get full text

Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial by Hambardzumyan, Karen, Bolce, Rebecca, Saevarsdottir, Saedis, Cruickshank, Scott E, Sasso, Eric H, Chernoff, David, Forslind, Kristina, Petersson, Ingemar F, Geborek, Pierre, van Vollenhoven, Ronald F

“…Prediction of radiographic progression (RP) in early rheumatoid arthritis (eRA) would be very useful for optimal choice among available therapies. We evaluated…”
Get more information

Longterm Safety of Patients Receiving Rituximab in Rheumatoid Arthritis Clinical Trials by VAN VOLLENHOVEN, Ronald F, EMERY, Paul, BINGHAM, Clifton O, KEYSTONE, Edward C, FLEISCHMANN, Roy, FURST, Daniel E, MACEY, Katherine, SWEETSER, Marianne, KELMAN, Ariella, RAO, Ravi

“…Objective. To evaluate the longterm safety of rituximab in clinical trials in patients with rheumatoid arthritis (RA). Methods. Pooled analysis of safety data,…”
Get full text

Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: Studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging study in patients with systemic lupus erythematosus by Bengtsson, Anders A., Sturfelt, Gunnar, Lood, Christian, Rönnblom, Lars, van Vollenhoven, Ronald F., Axelsson, Bengt, Sparre, Birgitta, Tuvesson, Helén, Öhman, Marie Wallén, Leanderson, Tomas

“…Objective To assess the efficacy of paquinimod, a new immunomodulatory small molecule, in a murine lupus model, and to evaluate its pharmacokinetics and…”
Get full text